Abstract
In this contribution, we focused on evaluating a novel compound developed by our group. This molecule, derived from glutamine (Gln) and valproic acid (VPA), denominated (S)- 5-amino-2-(heptan-4-ylamino)-5-oxopentanoic acid (Gln-VPA), was submitted to docking studies on histone deacetylase 8 (HDAC8) to explore its non-bonded interactions. The theoretical results were validated in HeLa cells as a cancer cell model and in human dermal fibroblasts as a normal cell model. The effects of Gln-VPA on HeLa and normal fibroblasts in terms of cell survival and the ability to inhibit HDAC activity in nude nuclear proteins and in nuclear proteins of whole cells treated for 24 h were analyzed. The HeLa cell cycle was analyzed after 24 and 48 h of treatment with Gln-VPA. The docking studies show that Gln-VPA can reach the catalytic site of HDAC8. Gln-VPA was organically synthesized with a purity greater than 97%, and its structure was validated using mass spectrometry, nuclear magnetic resonance and infrared spectroscopy. Gln-VPA showed a similar effect to VPA as an HDAC inhibitor but with less toxicity to fibroblasts. Although Gln-VPA was less efficient than VPA in reducing the survival of HeLa cells, it could be studied for use as a cancer cell sensitizer.
Keywords: HDAC inhibitors, VPA derivatives, HeLa cells.
Anti-Cancer Agents in Medicinal Chemistry
Title:Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells
Volume: 16 Issue: 11
Author(s): F. Martínez-Ramos, G. R. Luna-Palencia, I. Vásquez-Moctezuma, D. Méndez-Luna, M. J. Fragoso-Vázquez, J. Trujillo-Ferrara, M. A. Meraz-Ríos, J. E. Mendieta-Wejebe and J. Correa-Basurto
Affiliation:
Keywords: HDAC inhibitors, VPA derivatives, HeLa cells.
Abstract: In this contribution, we focused on evaluating a novel compound developed by our group. This molecule, derived from glutamine (Gln) and valproic acid (VPA), denominated (S)- 5-amino-2-(heptan-4-ylamino)-5-oxopentanoic acid (Gln-VPA), was submitted to docking studies on histone deacetylase 8 (HDAC8) to explore its non-bonded interactions. The theoretical results were validated in HeLa cells as a cancer cell model and in human dermal fibroblasts as a normal cell model. The effects of Gln-VPA on HeLa and normal fibroblasts in terms of cell survival and the ability to inhibit HDAC activity in nude nuclear proteins and in nuclear proteins of whole cells treated for 24 h were analyzed. The HeLa cell cycle was analyzed after 24 and 48 h of treatment with Gln-VPA. The docking studies show that Gln-VPA can reach the catalytic site of HDAC8. Gln-VPA was organically synthesized with a purity greater than 97%, and its structure was validated using mass spectrometry, nuclear magnetic resonance and infrared spectroscopy. Gln-VPA showed a similar effect to VPA as an HDAC inhibitor but with less toxicity to fibroblasts. Although Gln-VPA was less efficient than VPA in reducing the survival of HeLa cells, it could be studied for use as a cancer cell sensitizer.
Export Options
About this article
Cite this article as:
Martínez-Ramos F., Luna-Palencia R. G., Vásquez-Moctezuma I., Méndez-Luna D., Fragoso-Vázquez J. M., Trujillo-Ferrara J., Meraz-Ríos A. M., Mendieta-Wejebe E. J. and Correa-Basurto J., Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1871520616666160204111158
DOI https://dx.doi.org/10.2174/1871520616666160204111158 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Electrochemical Cell-based Biosensors for Biomedical Applications
Current Topics in Medicinal Chemistry Back to the Future: COX-2 Inhibitors for Chemoprevention and Cancer Therapy
Mini-Reviews in Medicinal Chemistry Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Recent Development, Applications, and Perspectives of Mesoporous Silica Particles in Medicine and Biotechnology
Current Medicinal Chemistry Maternal Sepsis: Current Approaches to Recognition and Clinical Management
Current Women`s Health Reviews Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Overview of Genomic Insights into Chicken Growth Traits Based on Genome- Wide Association Study and microRNA Regulation
Current Genomics A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design